New Abstract Accepted for Oral Presentation at Scandinavian Congress of Rheumatology (SCR) 2023
We are delighted to announce that the encore presentation of the abstract titled “Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study,” initially featured at EULAR 2023, has been accepted for oral presentation at the prestigious Scandinavian Congress of Rheumatology (SCR) 2023 annual meeting.
This exceptional recognition underscores the significance of the research findings and their potential impact on the field of rheumatology. The study, conducted as the MOSAIC Study, investigates the impact of Apremilast in reducing inflammation, as assessed through MRI scans of the hand, in patients battling Psoriatic Arthritis.
The Phase 4 MOSAIC Study has garnered attention for its innovative approach to understanding the effects of Apremilast, a promising therapy for Psoriatic Arthritis patients. The primary results revealed during the EULAR 2023 conference have already generated significant interest among medical professionals, researchers, and patients seeking the latest advancements in rheumatological care.
The SCR 2023 annual meeting, known for its dedication to fostering collaboration and showcasing cutting-edge research in rheumatology, provides an ideal platform for the encore presentation of these pivotal findings. The opportunity to share this research with an esteemed audience of experts and peers at SCR 2023 further highlights its potential to improve the lives of individuals affected by Psoriatic Arthritis.
Details of the presentation:
Title: Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
Presenter: Mikael Boesen, MD, PhD
Congress: Scandinavian Congress of Rheumatology (SCR) 2023 annual meeting.
Clinical trial: https://classic.clinicaltrials.gov/ct2/show/NCT03783026
Authors: Philip Mease, Mikael Boesen, W Maksymowych, Mikkel Ostergaard, Michael Bubb, Robert Lambert, Olga Kubassova, Reddy, Jyotsna, Colgan, Stephen, Klyachkin, Yuri, Deignan, Cynthia, Tang, Lihua, Cheng, Sue
We invite attendees of the Scandinavian Congress of Rheumatology (SCR) 2023 to join us for this clinically relevant presentation, as we delve deeper into the transformative implications of Apremilast in the management of Psoriatic Arthritis.
For media inquiries, interview requests, or further information about the presentation and research, please contact
IAG is an imaging expert organization dedicated to advancing the understanding and treatment of rheumatological conditions through cutting-edge research and collaboration with the global medical community. Our mission is to support drug developers on their mission to improve the quality of life for individuals affected by these diseases and to drive innovation in rheumatology.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit Amgen.com
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin